Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Electrofusion DC Vaccine in Stage IV Renal Cell Carcinoma
NCT00625755Phase 2Completed
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Dec 2002
- Primary completion
- Jun 2005
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Electrofusion dendritic cell vaccine in renal cell carcinoma (RCC), sponsored by Beth Israel Deaconess Medical Center. Primary endpoint: Safety of 3 serial vaccinations. Started Dec 2002; status: completed.
02
Drugs
Electrofusion dendritic cell vaccine
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00625755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00625755.